CVD-COG

CerebroVascular Disease-Cognition trial

Purpose:

The purpose of CVD-COG is to investigate whether Cilostazol and/or Isosorbide Mononitrate are effective in treating cSVD in patients who have had non-lacunar ischaemic strokes.

Who is eligible:

Participants who are 7 days from diagnosis with a non lacunar stroke or TIA syndrome are eligible for recruitment. The research team will screen against a more detailed criteria and will take consent from the patient or their representative

Treatment allocation and blinding:

Participants will be randomly assigned to one of four treatment groups:

1. **Cilostazol** only.
2. **Isosorbide mononitrate** only.
3. Both **cilostazol** and **isosorbide mononitrate.**
4. Neither **cilostazol** nor **isosorbide mononitrate**.

Participants who are already on oral anticoagulation will only be randomised between groups 2 and 4 (Isosorbide mononitrate only or no treatment).

If the participant becomes unwell in any way, please inform the research team as soon as possible. Please make the research team aware of any issues with the administration or unblinding of trial treatment.

<Insert local research team contact details here>

PI Number

Research Team Contact:

Telephone:

Email:

Further information can be found at:

<Placeholder QR>

stroke.nottingham.ac.uk/CVD-COG

Funded by Alzheimer's Society

The University of Nottingham

UNITED KINGDOM · CHINA · MALAYSIA